Objective. The current study aimed to (1) describe communication patterns between oncologists and breast cancer patients regarding the use of complementary and alternative medicine (CAM) and (2) assess the relationship between CAM discussions and anxiety levels. Methods. Interaction analysis of audiotaped initial consultations of 102 early-stage breast cancer patients with Australian and New Zealand oncologists was carried out. Preconsultation and postconsultation anxiety levels were assessed using the State-Trait Anxiety Inventory. Results. At least 1 instance of CAM discussion was found in 24 of the 102 consultations (24%). CAM discussions were mainly patient initiated (73%). The most common doctor's response to a patient's mention of CAM was encouragement (38%), although 23% of CAM references elicited a discouraging comment, and 20% were ignored. No patient demographics were significantly associated with CAM discussion. Patients who discussed CAM reported higher preconsultation and postconsultation anxiety levels than those who did not discuss CAM. Conclusions. CAM discussions during initial consultations between early-stage breast cancer patients and oncologists appear to be limited and linked with higher patient anxiety before and after the consultation. These findings indicate that doctors require further education about CAM therapies and supplements as well as guidance in how to raise and effectively discuss CAM issues with concern for their safety while balancing respect for the patients' beliefs.
Introduction
Complementary and alternative medicine (CAM) refers to a group of diverse medical and health care systems, practices, and products that are not generally considered part of conventional medicine. 1 According to recent European and American surveys, 2, 3 CAM is used by 31% to 95% of breast cancer patients. In a national US study involving 2527 breast cancer survivors, Saxe et al 4 reported that 80% used some form of CAM, and of these, 28% used CAM for cancerrelated reasons. Although there is a lack of scientifically credible research to support CAM influencing survival time, adoption of CAM may aid active coping during and following the treatment process, 5, 6 assist in minimizing adverse side effects of conventional treatment, 4, 6, 7 and/or more closely reflect patient values and life philosophies, compared with allopathic medicine. 8 Given the high prevalence of CAM use as an adjunct to standard care among cancer patients and the potential for harmful interactions between certain types of CAM and conventional medicines, 9 it is important that clinicians and patients engage in an open dialogue about CAM use to ensure safe and integrated health care practices. 10, 11 However, a substantial proportion of cancer patients (23% 12 to 60% 5 ) do not disclose CAM use to their oncologists, and oncologists rarely initiate such discussions. 2, [12] [13] [14] The relatively high rate of nondisclosure regarding CAM use may be a result of many factors, such as patients' fear of a negative response from oncologists to the idea of using CAM, 12, 15 a perception that oncologists may not be interested in patients' use of CAM, 2,15 the physician's unfamiliarity with CAM, 4 the physician's failure to ask about CAM, 4 a patient's belief that discussing CAM is not relevant or related to his/her conventional treatment, 4 a patient not being aware that he/she is using CAM, 4 or patients' inability to articulate their concerns and questions regarding CAM. 16 Oncologists may not initiate discussion of CAM because of scepticism regarding the efficacy of CAM, not knowing how to respond to questions concerning CAM, or apprehension about initiating a time-consuming discussion. 6 The lack of discussion regarding CAM use may also be exacerbated by a common belief among oncologists that CAM is usually discussed with another health professional. Hann et al 17 asked 147 oncologists, 183 nurses, and 219 social workers about their experiences and perceptions regarding discussion of CAM during consultations. Only 21% of oncologists reported initiating discussions about CAM, although 63% said that they felt comfortable discussing CAM, and 48% thought that such discussions would enhance doctorpatient communication. The majority of oncologists (87%) thought that CAM was most often discussed with another medical staff member. A similar study found that although the 79 oncologists surveyed were generally enthusiastic and supportive of patients' CAM use, 43% reported broaching the subject "sometimes" and only 20% "often or very often," many believing that CAM discussion would most likely take place with nurses. 13 The opportunity to ensure patient safety and maximize favorable outcomes may be compromised by patients' reluctance to disclose CAM use and doctors' failure to initiate discussions of CAM. Discussing CAM use could clarify any potential patient misconceptions about its safety, evidence base, and efficacy and also enhance relationship building between the patient and oncologist 13, 15 by building rapport and fostering confidence and trust. 4 Discussion about CAM could also have a positive impact on patient outcomes 18 because patients who feel that they are listened to and that their oncologists are interested in their personal situation seem more satisfied with the consultation. This could lead to increased satisfaction with communication during the consultation, which can in turn affect patients' levels of anxiety, 19 depression, 19 and compliance. 20 Open communication about CAM may also benefit physicians by reducing the likelihood of litigation and malpractice. 4 Doctors who are good listeners, understand and respond to patients' needs, and encourage patients to discuss their concerns have been shown to have decreased malpractice risk. 4 Despite the potential benefits of CAM discussion between patients and health care providers, little research has been done in this area. To our knowledge, only 1 study to date has investigated the relationship between discussion of CAM and patient characteristics and outcomes. 14 In this Australian study, Schofield et al 14 found an association between CAM discussion and higher levels of "fighting spirit," "anxious preoccupation" with having cancer, and lower levels of "fatalism" about their disease. Although these coping mechanisms were associated with CAM discussion, no association between CAM discussion and patient anxiety levels was found. 14 Given the widespread unregulated use of CAM by cancer patients in Australia, further research is needed to explore possible associations between CAM discussion and patient outcomes.
The current study aimed to (1) describe patterns of CAM-related oncologist-patient communication in the early-stage (stages I or II) breast cancer setting using an Australian and New Zealand sample of surgical, radiation, and medical oncologists and (2) assess the impact of CAM discussions on breast cancer patients' anxiety levels. It was hypothesized that compared with those who did not discuss CAM (non-CAM group), women who had such discussions with their oncologists (CAM group) would have the following characteristics: (1) they would be younger, more educated, and of higher occupational status, and (2) they would not differ in anxiety levels.
Methods Design
The transcripts of audiotaped oncologist-patient consultations and patient data used in this study were obtained from 2 previous studies investigating the effect of interventions aimed at improving doctor-patient communication, conducted by our research unit. 21, 22 In both studies, consecutive patients with whom treatment options would be discussed were invited to participate by either their oncologist or a research nurse. Patients were informed that their consultation would be audiotaped before consenting to participate.
Oncologists were asked to audiotape their initial consultations with consenting patients, who also completed a questionnaire prior to, and immediately following, the initial consultation with their oncologist. Participating patients and oncologists were blind to the analysis of CAM discussions, and therefore, communication patterns depicted within the current consultations are likely to reflect true discussions of this topic in this setting. Ethics approval for the current study was obtained from the University of Sydney Human Research Ethics committee.
Participants
Early-stage (stages I or II) breast cancer patients attending initial consultations with their surgical, radiation, or medical oncologist at a public hospital in Australia or New Zealand were invited to participate in the study. Australia and New Zealand both have a public health system, although in Australia, there are tax incentives to join a private health fund. Eligibility criteria included the following: (1) age >18 years, (2) recent diagnosis of early-stage breast cancer, (3) attending a consultation to discuss available treatment options, (4) having adequate English-speaking skills, and (5) being mentally and physically capable of giving informed consent to participate. Complete transcripts of 102 patients' initial consultations with 24 oncologists were analyzed in the study.
Coding
Audiotaped consultations were transcribed in full and read by one of the researchers (LH) to identify those that involved CAM discussions. Incomplete transcripts (ie, those from audiotapes that were inaudible, started late, or finished early) were excluded from analysis (n = 12). The transcripts containing CAM discussions were coded using the coding system framework used by Schofield et al, 14 developed on the basis of a literature review and content analysis of audiotaped oncologist-patient consultations. It enables identification of various facets of oncologist-patient communication regarding CAM (see Table 1 ). An instance of CAM discussion was coded on each separate occasion when CAM was discussed, independently from previous occasions in terms of subject matter or timing. In the original study, the coding system was found to have an average interrater k of 0.88. In the current study, 10% of transcripts (ie, 10 consultations) were coded by a second researcher to determine interrater reliability. Average interrater k was 0.83, indicating a high level of agreement.
Measures
Anxiety levels were measured using the State-Trait Anxiety Scale, which consists of 20 items measuring state anxiety. Scores range from 20 to 80; high scores indicate greater levels of anxiety. Internal consistency has been found to be very high in several normative samples, with Cronbach's as of more than .90. 23 Patients' demographic items included age, gender, marital status, education, occupation, place of birth, first language spoken, and relevant health training.
Statistical Analyses
The nature of CAM discussions and demographic factors were described using frequency distributions. Chi-square Analysis was used to determine group differences in demographic characteristics. Independent sample t tests were used to determine the association between CAM discussion and anxiety. General linear regression was used to explore group differences in anxiety.
Results
All eligible doctors (n = 24) and 78% of eligible patients (n = 102) consented to the 2 original studies. Patients' and clinicians' demographic characteristics are shown in Tables 2 and  3 
Patterns of CAM Discussion
Reference to CAM use was identified in 24 (24%) out of 102 consultations. One instance of CAM discussion was found in 12 consultations and 2 instances in 10 consultations; 2 consultations contained more than 3 mentions of CAM. Thus, a total of 40 instances of CAM discussion in 24 consultations were identified.
The 3 most common types of CAM discussed included the following: vitamins and antioxidants (22.5%), followed by positive thinking/stress reduction techniques (20%), and changes in diet (17.5%; see Table 1 ). Nearly three quarters of CAM discussions (72.5%) were initiated by the patient, one quarter were initiated by the doctor, and 1 discussion was initiated by kin (see Table 1 ). The most common way in which patients and doctors initiated a CAM discussion was by either making a comment or offering a cue (50%). For example, one oncologist initiated discussion about CAM by commenting that "one thing you need to avoid is large amounts of vitamin C." An example of a patient initiating discussion by presenting a cue to the oncologist was, "A friend of mine, she had breast cancer and she had some tapes, she did yoga and things like positive thinking."
The overall response of the oncologist to the CAM discussed was one of encouragement in more than a third of cases (37.5%). For instance, one oncologist noted, Positive attitude, yes that's a good idea. I mean all the evidence suggests that if you can have a sort of fighting spirit, positive attitude and so on, you can by and large enjoy life more and such evidence that there is, suggests that they probably live longer any how. However, the second most common overall response of the oncologist was a discouraging comment about CAM (23%). The majority of these comments revolved around the idea that there is a lack of scientific evidence to support both the efficacy and safety of CAM in treating breast cancer. An example of a discouraging response was, "If you say you should be on megavitamins-well I don't know of the evidence but it doesn't help." In 20% of the consultations in which CAM was mentioned, the oncologist ignored the patient's attempts to discuss CAM. For instance, in one example, the patient stated that they were taking "natural stuff . . . vitamins," to which the oncologist replied, "And are you a lady of leisure or do you work?" Oncologists used evidence-based arguments in only 25% of discussions about CAM; likewise CAM interference with conventional treatment was mentioned in only 20% of cases.
Variables Associated With CAM Discussion
Chi-square Analysis and independent sample t tests revealed no significant differences in the demographic characteristics of patients who discussed CAM (CAM group) and those who did not discuss CAM (non-CAM group) during their consultation.
Patient Anxiety Levels
As Table 4 indicates, preconsultation and postconsultation anxiety levels were significantly higher in the CAM group compared with the non-CAM group (t PRE = 2.04, P = .044, df = 100; t POST = 2.23, P = .029, df = 83). Change in anxiety was not affected by the occurrence of CAM discussion (F = 2.33; P = .131; df = 83).
Discussion
This study investigated the pattern of CAM-related communication between oncologists and early-stage breast cancer patients during audiotaped initial consultations and assessed the impact of CAM discussions on patient levels of anxiety. Only a quarter (24%) of the 102 consultations examined featured discussions of CAM. Thus, reference to CAM occurred much less frequently than reported in past studies. 12 However, in contrast to previous research, which has typically involved a mixed sample of patients regarding cancer type and stage, the current study only included patients with early-stage breast cancer and, therefore, excluded cancer patients with metastases, which is a known predictor of CAM use among cancer patients. 24 Saxe et al 4 found that approximately 28% of those who used CAM for cancerrelated purposes did not disclose or only partially disclosed their visits to CAM practitioners to their physicians. The most popular types of CAM discussed in the consultations were vitamins, positive thinking, and dietary changes, supporting previous findings that these are the 3 most commonly used and discussed CAM modalities. 14, 25 Perhaps the large volume of research conducted on these popular types of CAM provides patients with the information and evidence necessary to make them feel comfortable about discussing them with their oncologists. Similarly, the absence of discussion about more radical forms of CAM such as shark cartilage and coffee enemas may be a consequence of the stigma associated with such CAM and patient apprehension about receiving a negative response from the oncologist to more unconventional types of CAM. It may also reflect the infrequent use of these CAM types, particularly among people with early-stage disease. 24 The majority of CAM discussions were initiated by patients (72.5%). This finding is consistent with previous research, which shows that oncologists are hesitant to initiate discussion of CAM. 14, 17 The disparity in the rate of patient-and oncologist-initiated CAM discussion may be a result of patients' greater belief in the efficacy of CAM. 6 However, it is important that oncologists take on the responsibility of initiating such discussions, given the high prevalence of nondisclosure regarding CAM use. 12 In this study, on 42.5% of occasions that CAM was mentioned, it was ignored or discouraged by the oncologist. Although oncologists may occasionally need to highlight potential negative effects of CAM, because the vast majority of the CAM discussed in these consultations have not been identified as harmful to cancer patients, 9 this may represent greater negativity than necessary. It has been suggested that doctors do not know how to discuss CAM or have an unnecessarily negative attitude to CAM use. 18 It is important that doctors discuss both the pros and cons of CAM use in a balanced way, so that patients can make an informed choice between treatment options, including CAM. Contrary to our hypothesis, patients' demographic characteristics did not affect the likelihood of CAM being discussed during consultations. Whereas the lack of any significant association between CAM discussion and marital status, occupation, or medical training is consistent with previous research, 13 some research has found that a higher education level and a more CAM-friendly and sensitive environment is related to CAM disclosure. 4 The absence of any differences in the incidence of CAM discussion in our study according to age and educational status is surprising, and it is possible that our study lacked the power to detect such effects, with only 24% of patients discussing CAM.
Interestingly, patients involved in CAM discussions were found to have higher anxiety levels than those attending consultations where CAM was not discussed. More anxious patients may be more likely to explore every possible treatment option for their cancer, including CAM. This explanation is consistent with previous research showing that CAM use is linked with helplessness, depression, poorer quality of life, and more physical symptoms. 24, 26 Another potential explanation is that patients who plan to discuss CAM may feel more anxious before their consultation because they may fear getting a negative response from the oncologist. Finally, patients interested in or using CAM may have negative views toward or may have had bad experiences with allopathic treatment 14 and, thus, are anxious because of their dissatisfaction with conventional treatment methods.
Study Limitations
The findings of the current study may have been restricted by the relatively small sample of consultations (n = 102), thus reducing our capacity to detect small-medium effects and also the generalizability of the findings. Furthermore, we only captured initial oncology consultations, and it is possible that CAM was discussed at subsequent consultations, although major treatment decisions were often made in the consultations analyzed. Although the discussion of CAM and the factors surrounding the discussion were extensively assessed, the lack of nonverbal communication indicators is a major limitation of the current analysis.
Finally, the study did not collect data regarding patient and oncologist views about CAM use or the actual use of CAM among the patients.
Conclusion
The current study used an objective coding system to study the pattern of CAM discussions in a large sample of clinicians (n = 24), with many findings supporting previous research. 14 The results highlighted the relative lack of CAM discussions during initial consultations between early-stage breast cancer patients and oncologists and the relative scarcity of positive responses when such discussions occurred. This study indicated that CAM discussion appears to be linked with higher patient anxiety before and after the consultation.
Given the evidence suggesting that patients using CAM may have higher levels of psychological distress and symptoms, it is vital for oncologists to know why their patients are seeking out CAM. This knowledge will enable them to give an appropriate response and meet their patients' supportive care needs. CAM discussions could also be viewed as an opportunity to explore the holistic needs of the patient. However, to date, oncologists have had limited access to education about CAM therapies and supplements and little guidance on how to initiate and conduct a balanced discussion about CAM.
Such gaps in clinical practice are being addressed in recent research. For example, a study evaluating a CAM training course found that it was effective in improving doctors' and nurses' understanding and knowledge of evidence-based CAM research as well as doctor-patient communication on this topic. 27 Furthermore, evidence-based guidelines on effectively discussing CAM in conventional oncology settings have recently been formulated. 28 These guidelines, forming the basis of a new communication skills training program, are presented as a sequence of recommended steps: (1) elicit the person's understanding of his/ her situation, (2) respect cultural and linguistic diversity and different beliefs, (3) ask questions about CAM use at critical points in the illness trajectory, (4) explore details and actively listen, (5) respond to the person's emotional state, (6) discuss relevant concerns about CAM while respecting the person's beliefs, (7) provide balanced, evidence-based advice; (8) summarize CAM-related discussions, (9) document the discussion, and (10) monitor and follow up CAM discussions at subsequent consultations. 28 Together with further education about CAM therapies and supplements, these guidelines may assist health professionals in initiating respectful, wellinformed, and balanced discussions with patients about CAM.
